Subscribe
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma
Articles
Articles
Pomalidomide/Dexamethasone/Ixazomib versus Pomalidomide/Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma: Results of Phase 1/2 Alliance A061202
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read More
Novel Kinesin Spindle Protein Inhibitor Filanesib Plus Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read More
Ibrutinib plus Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma: Results of an Ongoing Phase 1/2b Study (PCYC-1119)
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read More
Pembrolizumab plus Lenalidomide/Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (KEYNOTE-023)
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read More
Pembrolizumab, Pomalidomide, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 2 Study
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read More
Daratumumab plus Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Results of the GEN503 Study
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read More
Elotuzumab plus Bortezomib and Dexamethasone versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 2 Study (CA204-009T)
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read More
Dose-Finding Phase 2 Trial of Single-Agent Isatuximab in Relapsed/Refractory Multiple Myeloma
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read More
Daratumumab plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a 4-Arm Phase 1b Study
ASH 2015 - Multiple Myeloma
Conference Correspondent
Read More
Ixazomib plus Lenalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM): Results of the Phase 3 Tourmaline-MM1 Study
ASH 2015 - Multiple Myeloma
Conference Correspondent
Read More
Page 179 of 330
176
177
178
179
180
181
182
Top Trending Articles
1.
FDA Approves Acalabrutinib and Venetoclax Combination for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2.
FDA Launches Unified Adverse Event Monitoring System to Enhance Transparency and Efficiency
3.
Financial Toxicity in Cancer Care: Why the Conversation Must Start Before Treatment Begins
Jan Hailey, MHL, CMC, CMCO, CMIS, CMOM, CMCA-E/M
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma